BFC Planning’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
Other funds holding LCTX
BFC Planning's LCTX Position: Q3 2026 in Review
BFC Planning held its Lineage Cell Therapeutics (LCTX) position steady in Q3 2026 at 270,170 shares worth $258K. The position accounts for 0.01% of the portfolio, ranked #845.
BFC Planning first reported a position in LCTX in Q3 2024 and has held it in 9 quarters since. The position peaked at $457K in Q3 2025. 110 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.
- BFC Planning held 270,170 shares of Lineage Cell Therapeutics worth $258K as of Q3 2026.
- BFC Planning left its Lineage Cell Therapeutics share count unchanged in Q3 2026.
- Lineage Cell Therapeutics made up 0.01% of BFC Planning's portfolio in Q3 2026, its #845 holding.
- BFC Planning first reported a position in Lineage Cell Therapeutics in Q3 2024 and has held it in 9 quarters since.
- BFC Planning's Lineage Cell Therapeutics position peaked at $457K in Q3 2025.
- 110 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.